Clinical Trial

Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were treated with Xuesaitong soft capsules (mainly containing ginsenosides) for 12 weeks.
Trial Details
NCT Number NCT06845254
Lead Sponsor Xiyuan Hospital of China Academy of Chinese Medical Sciences
Conditions Acute Coronary Syndrome
Enrollment 400 participants
Start Date 2025-03-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25